Navigation Links
China-Biotics Appoints New Chief Operating Officer
Date:11/11/2010

SHANGHAI, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: CHBT) the leading developer, manufacturer and distributor of probiotics products in China, today announced the appointment of Dr. Hui S. Chang as Chief Operating Officer, effective immediately.

Dr. Chang brings 15 years of biopharmaceutical project management experience and excellent research capabilities. Prior to joining China-Biotics, Dr. Chang served as the president of a consulting service for a Sino-U.S. joint biopharmaceutical program, where he led the scientific design, development, clinical trials, production and quality control for viral vaccines and antibodies. He reported to the State Administration of Foreign Experts Affairs and played a key role in generating profits on the completed contract. Dr. Chang was previously a senior manager of Nabi Biopharmaceuticals, where he supervised the development and production of bacterial and viral vaccines, developed biological potency and immunological methods and managed the development of assays for quality control and clinical testing. Earlier, Dr. Chang served as a manager at Vaccinnate, a North American bio-vaccine company, where he led the design, GMP production and clinical testing of viral vaccines. Previously, Dr. Chang was a research scientist with Cambridge Biotech, where he specialized in the production and quality control of monoclonal biological products, protein products as well as HIV and HTLV antigen. Dr. Chang started his professional career at North AM VAC Inc. in 1989.

Dr. Chang holds a Ph.D. in vaccine development focusing on biochemistry and immunology as well as an MBA with concentration in finance and logistics in the vaccine industry from Johns Hopkins University. He also has a Bachelor of Science in biology from the University of Maryland. Dr. Chang has also received certified training in Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Safety Practice (GSP) procedures. Dr. Chang is fluent in English and mandarin Chinese.

Mr. Jinan Song, Chairman and CEO of China-Biotics, commented, "We are very pleased that China-Biotics has been able to attract such a qualified candidate for this crucial position. Dr. Chang's solid biotech background, advanced project management track record, and his excellent knowledge in business and finance will make him a strong COO and desirable addition to our team. China-Biotics continues to build a strong management team to support our expanding bulk business in both the dairy and animal feed markets in China."

About China-BioticsChina-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC mainly through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com .Contact:Travis Cai Chief Financial OfficerChina-Biotics, Inc.traviscai@chn-biotics.comShiwei Yin/Dixon Chen  Grayling646-284-9474shiwei.yin@grayling.com dixon.chen@grayling.com
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9
2. China-Biotics Hosted its First Investor Day Event
3. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
4. China-Biotics to Report Fiscal Year 2011 First Quarter Financial Results on August 9
5. China-Biotics Provides Further Updates on Qingpu New Facility
6. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
7. China-Biotics to Report Fourth Quarter and Fiscal Year 2010 Financial Results on June 11
8. China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
11. China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... YORK , January 20, 2017 ... Organization, cancer is one of leading causes of death ... 2012. Although the number of cancer related deaths increased ... 1990. Rising in incidence rate of various cancers continues ... to a research report by Global Market Insights, Inc. ...
(Date:1/19/2017)... Jan. 19, 2017  Market Research Future has a half cooked ... Liquid Biopsy is growing rapidly and expected to reach USD 450 ... Highlights ... Liquid Biopsy Market has been assessed as a swiftly growing market ... boom in the coming future. There has been a tremendous growth ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CESĀ® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):